FDA Greenlights Home Tests for Sneaky STI Germs
Published Date: 10/9/2026
Rule
Summary
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Home STI nucleic-acid tests moved to Class II
The FDA officially classified systems that detect nucleic acid from non-viral sexually transmitted infection (STI) organisms using home-collected specimens as Class II (special controls). This classification is effective October 9, 2026 and was applicable November 15, 2023, and applies to devices intended for prescription or over-the-counter use. The FDA says Class II provides a reasonable assurance of safety and will help enhance patient access by reducing regulatory burdens compared with automatic Class III assignment.
New safety, labeling, and website requirements
Manufacturers must follow detailed special controls for these home collection STI tests that protect users. Required measures include clear user-facing labeling and FAQs, warnings (for example: a negative test does not rule out other infections and the kit is not a substitute for a healthcare visit), accessioning criteria for labs, and a prominent hyperlink to the manufacturer website with instructions, performance data, and technical assistance information.
Easier 510(k) pathway but with study and validation obligations
By being classified into Class II via De Novo, this device type can serve as a predicate so other sponsors can use the 510(k) pathway rather than automatic Class III routes, which FDA says reduces regulatory burdens. At the same time, the device type remains subject to premarket notification under section 510(k) (FDA has not exempted it) and manufacturers must meet detailed special controls, including design verification and validation, prospective clinical studies with self-collected samples, analytical studies (limit of detection, cross-reactivity, etc.), usability and label comprehension studies, and software validation as applicable.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-20726, Medical Devices; Cardiovascular Devices; Classification of the Infant Pulse Rate and Oxygen Saturation Monitor for Over-the-Counter Use
The FDA is officially classifying infant pulse rate and oxygen saturation monitors for over-the-counter use as Class II devices with special safety rules. This change makes these monitors easier to get, safer to use, and less costly to bring to market. Starting October 9, 2026, parents and caregivers can expect better access to these helpful devices without extra red tape.
Next: 2026-20736, Air Plan Approval; Michigan; Clean Data Determination for the Berrien, MI and Muskegon, MI Areas for the 2015 Ozone Standards
Great news for folks in Berrien and Muskegon counties, Michigan! The EPA says these areas have cleaned up their air enough to meet the 2015 ozone standards. Because of this, they don’t have to submit extra air quality plans or controls for now, saving time and effort as long as the air stays clean.